Clene Inc. Announces $4.0M Private Stock Offering

What Happened

• Clene Inc. (CLNN) announced on September 15, 2026 that it entered into a Securities Purchase Agreement to issue and sell 1,219,513 shares of common stock at $3.28 per share. The aggregate gross proceeds are approximately $4.0 million, and the company expects the offering to close on September 17, 2026. Purchasers include certain existing stockholders, among them some of Clene’s directors and officers. The offering is being conducted without a placement agent, underwriter, broker or dealer, and Clene is not paying underwriting discounts or commissions.

Key Details

• Shares to be sold: 1,219,513 common shares.
• Price per share: $3.28; approximate gross proceeds: $4.0 million.
• Expected closing date: September 17, 2026.
• Use of proceeds: general corporate purposes, including support for regulatory dialogue and preparation of regulatory filings and a new drug application for lead candidate CNM‑Au8 (including expanded access protocols), potential commercialization efforts, and manufacturing expansion.
• Offering undertaken under the company’s Form S‑3 registration statement and a prospectus supplement filed September 16, 2026; legal opinion from Dorsey & Whitney LLP was filed as an exhibit.

Why It Matters

• This transaction provides Clene with near‑term cash (about $4.0M) to fund ongoing regulatory and development activities for CNM‑Au8 and other corporate needs. Because purchasers include insiders (directors and officers), the funding comes partly from existing shareholders rather than third‑party investors; investors may view insider participation as a sign of support but should note potential dilution from the newly issued shares. The company stated the offering has minimal transaction costs since no underwriters or commissions are involved.